JPWO2022043315A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022043315A5 JPWO2022043315A5 JP2023513271A JP2023513271A JPWO2022043315A5 JP WO2022043315 A5 JPWO2022043315 A5 JP WO2022043315A5 JP 2023513271 A JP2023513271 A JP 2023513271A JP 2023513271 A JP2023513271 A JP 2023513271A JP WO2022043315 A5 JPWO2022043315 A5 JP WO2022043315A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- polypeptide
- cells
- car
- recombinant nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 34
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 13
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 12
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 12
- 108010058905 CD44v6 antigen Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 102000004127 Cytokines Human genes 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 230000003308 immunostimulating effect Effects 0.000 claims 6
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000003776 cleavage reaction Methods 0.000 claims 5
- 230000007017 scission Effects 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000000735 allogeneic effect Effects 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 claims 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108050000299 Chemokine receptor Proteins 0.000 claims 2
- 102000009410 Chemokine receptor Human genes 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 101710107699 Interleukin-15 receptor subunit alpha Proteins 0.000 claims 2
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108091008927 CC chemokine receptors Proteins 0.000 claims 1
- 102000005674 CCR Receptors Human genes 0.000 claims 1
- 101150066398 CXCR4 gene Proteins 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004990 primary immune cell Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20192399.2 | 2020-08-24 | ||
| EP20192399 | 2020-08-24 | ||
| EP20205696.6 | 2020-11-04 | ||
| EP20205696 | 2020-11-04 | ||
| PCT/EP2021/073369 WO2022043315A1 (en) | 2020-08-24 | 2021-08-24 | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540022A JP2023540022A (ja) | 2023-09-21 |
| JP2023540022A5 JP2023540022A5 (https=) | 2024-09-02 |
| JPWO2022043315A5 true JPWO2022043315A5 (https=) | 2024-09-02 |
Family
ID=77710751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513271A Pending JP2023540022A (ja) | 2020-08-24 | 2021-08-24 | チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにＣＤ４４ｖ６を認識するＣＡＲ発現細胞 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240009310A1 (https=) |
| EP (1) | EP4199959A1 (https=) |
| JP (1) | JP2023540022A (https=) |
| AU (1) | AU2021334107A1 (https=) |
| WO (1) | WO2022043315A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7849891B2 (ja) * | 2020-08-24 | 2026-04-22 | シャリテ－ウニベルジテーツメディツィン ベルリン | Ｃｅａを認識するキメラ抗原受容体（ｃａｒ）発現細胞 |
| WO2024093147A1 (zh) * | 2022-10-31 | 2024-05-10 | 南京元迈细胞生物科技有限公司 | 一种特异性结合CD44的v5外显子的抗体及其用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5460831A (en) | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6489458B2 (en) | 1997-03-11 | 2002-12-03 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
| EP1079688A1 (en) | 1998-05-26 | 2001-03-07 | Innogenetics N.V. | Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EP2160461B1 (en) | 2007-07-04 | 2012-08-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
| CA2984624A1 (en) * | 2015-03-18 | 2016-09-22 | Baylor College Of Medicine | Her2/erbb2 chimeric antigen receptor |
| WO2017040945A1 (en) * | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| AU2018231190B2 (en) * | 2017-03-08 | 2023-05-25 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| US11701405B2 (en) * | 2018-01-26 | 2023-07-18 | City Of Hope | Chimeric antigen receptors and methods for reducing toxicity |
| EP3784256A4 (en) * | 2018-04-27 | 2022-06-29 | Baylor College of Medicine | Car t cells with one or more interleukins |
-
2021
- 2021-08-24 EP EP21769099.9A patent/EP4199959A1/en active Pending
- 2021-08-24 US US18/042,550 patent/US20240009310A1/en active Pending
- 2021-08-24 WO PCT/EP2021/073369 patent/WO2022043315A1/en not_active Ceased
- 2021-08-24 JP JP2023513271A patent/JP2023540022A/ja active Pending
- 2021-08-24 AU AU2021334107A patent/AU2021334107A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7755890B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| US12410248B2 (en) | Chimeric antigen receptor and its use | |
| CN109880803B (zh) | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 | |
| Wilkie et al. | Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling | |
| US20220275052A1 (en) | Receptor | |
| JP2022109953A5 (https=) | ||
| JP2022169543A (ja) | 改善された養子ｔ細胞療法 | |
| US20210221906A1 (en) | Carbonic anhydrase ix specific chimeric antigen receptors and methods of use thereof | |
| CN109280086B (zh) | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 | |
| CN105331585A (zh) | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 | |
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| JP2021525534A5 (https=) | ||
| US20250197470A1 (en) | Pooling signaling and costimulatory domains in b7h6 chimeric antigen receptor | |
| WO2022007795A1 (zh) | 一种嵌合受体及其应用 | |
| CN115003700A (zh) | 促实体瘤浸润的增强型cart细胞及其制备方法和细胞药物 | |
| CN111892661A (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| Lo et al. | Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor | |
| CN114867490A (zh) | 细胞因子调控表达的免疫效应细胞 | |
| WO2022029431A1 (en) | Chimeric receptor binding tgf-beta | |
| CN114929863B (zh) | 共表达趋化因子受体的免疫效应细胞 | |
| WO2020259541A1 (zh) | 一种用于肿瘤治疗的嵌合抗原受体t淋巴细胞及其制备方法与应用 | |
| CN119907857A (zh) | 包含嵌合衔接子多肽的组合物和方法 | |
| CN111875708A (zh) | 一种嵌合抗原受体t淋巴细胞及其在制备治疗实体肿瘤的产品中的应用 | |
| CN112996819A (zh) | 细胞分选系统及使用方法 | |
| Mohammadi et al. | Immunotherapy Research And Textbook 3: T-cell transfer therapy and Monoclonal antibodies |